#USA #San Diego #Neurocrine Biosciences #INGREZZA #Mike Sibley

Exciting Leadership Changes at Neurocrine Biosciences

Neurocrine Biosciences, a prominent player in the biopharmaceutical sector, has recently made an important addition to its team with the appointment of Mike Sibley as the Senior Vice President and General Manager of their Neuropsychiatry franchise. This strategic move is aimed at advancing the company's ambitious goals in developing innovative treatments for neurological and psychiatric disorders.

Experienced Leadership

Mike Sibley brings over two decades of rich commercial experience in the biopharmaceutical industry, marking him as a suitable fit for this role. With a background that includes significant positions at well-known companies such as Sanofi, J.P. Morgan Chase, and Johnson & Johnson, Sibley's career trajectory has been defined by his ability to steer sales and marketing strategies toward success. Prior to joining Neurocrine, he served as General Manager for Sanofi’s Dermatology division and had held key roles in sales management.

Eric Benevich, Neurocrine’s Chief Commercial Officer, expressed confidence in Sibley’s leadership abilities, stating, "Mike is an accomplished leader with a strong record of leading high-performing sales and marketing teams and delivering results." This newly acquired leadership comes at a crucial time for Neurocrine, as the company continues to expand its market presence and innovate with their flagship neuropsychiatry product, INGREZZA®.

Focus on Patient Needs

Sibley acknowledges the significance of his new position within the company. "Neuropsychiatric conditions and movement disorders impact millions of people and their families," he stated. His primary goal will be to collaborate with various stakeholders—including healthcare providers and caregivers—to ensure that effective treatments reach those in need. His appointment aligns with Neurocrine’s mission to provide life-changing therapies for underserved patient populations suffering from debilitating health conditions.

The Neuropsychiatry division, with INGREZZA® as a cornerstone product, is focused on treating tardive dyskinesia, a serious movement disorder. Given the complexities associated with neuropsychiatric conditions, Sibley’s extensive industry experience will be crucial in navigating the challenges of this specialized field.

Neurocrine’s Legacy and Future

Neurocrine Biosciences has established itself as a leader in neuroscience-focused biopharmaceutical solutions over the past three decades. With an unwavering commitment to discovering and developing transformative therapies, the company addresses neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio also encompasses FDA-approved treatments for conditions like chorea associated with Huntington's disease and congenital adrenal hyperplasia, showcasing their commitment to providing comprehensive treatment options.

As Neurocrine embarks on its next chapter with Mike Sibley at the helm of the Neuropsychiatry franchise, the expectations are high for the company to continue its trajectory of growth and innovation. The ongoing development of the pipeline products positions Neurocrine competitively within the biopharmaceutical landscape, and patient advocates will be watching closely to see the advancements that emerge from this new leadership.

Conclusion

In conclusion, Mike Sibley’s appointment as Senior Vice President at Neurocrine Biosciences signals a promising direction for the company. With a focus on addressing the unmet needs of patients and a strong pipeline of therapies, Neurocrine is set to make a significant impact in the realm of neuropsychiatry, providing hope and support to those affected by these challenging conditions.